NCR Jan 2025 30.000 call
| Previous close | 3.5500 |
| Open | 3.6000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 30.00 |
| Expiry date | 2025-01-17 |
| Day's range | 3.5000 - 3.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 453 |
- Business Wire
NCR Voyix Corporation Announces Date of Third Quarter 2023 Earnings Conference Call
ATLANTA, November 02, 2023--NCR Voyix Corporation (previously known as NCR Corporation) (NYSE: VYX) ("NCR Voyix") announced today that consolidated financial results for the third quarter 2023 will be issued after the market close on November 9, 2023. The results will reflect the legacy NCR business, inclusive of NCR Atleos, which was spun-off as an independent publicly traded company on October 16, 2023.
Business WireNCR Corporation Changes Name to NCR Voyix Corporation
ATLANTA, October 16, 2023--NCR Corporation (NYSE: NCR), a leading enterprise technology provider, today announced a change of its name to NCR Voyix Corporation. This change reflects the company’s planned separation into two independent, publicly traded companies, NCR Voyix, focused on digital commerce, and NCR Atleos, focused on ATMs. The separation is expected to be completed on October 16, 2023, at the close of business.
- PR Newswire
NCR Atleos Set to Join S&P SmallCap 600
NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 18. S&P MidCap 400 constituent NCR Corp. (NYSE: NCR) is spinning off NCR Atleos in a transaction expected to be completed on October 17. Following the spin-off, the NCR parent will have a name and symbol change to NCR Voyix Corp. (NYSE: VYX) and will remain in the S&P MidCap 400. iTeos Therapeutics is no longer representative of t
